A Agilent Technologies Inc.

Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon

(NYSE: A) today announced the launch of the , a sensitive flow cytometer with five lasers and up to 30 fluorescence channels. The NovoCyte Penteon provides excellent sensitivity, resolution, speed, and flexibility. It has a large dynamic range of 7.2 log, along with fully automated compensation features, enabling users to pick up both dim and bright signals in the same run.

“The NovoCyte Penteon provides expanded capabilities of UV laser excitation that accommodate multicolor flow cytometry assays which are becoming increasingly sophisticated,” stated Xiaobo Wang, Ph.D., who joined Agilent from ACEA, as general manager of the Flow Cytometry and Real-Time Cell Analysis Business. “The NovoCyte Penteon is continuing the NovoCyte legacy of great cytometry performance matched with intuitiveness and simplicity of user experience.”

“NovoCyte Penteon is expanding Agilent’s offering of advanced flow cytometer instrumentation,” stated Todd Christian, vice president, and general manager of Agilent's Cell Analysis Division. “Agilent is committed to continuing our innovation for trusted cell analysis solutions, to support scientists of the world in their endeavor of scientific and therapeutic discovery for advancing the human condition.”

The resolution easily discerns particles in the range of 100 nanometers, and the precision fluidics are considered to be among the best on the market. Coupled with the power of the highly intuitive NovoExpress software package, the system can be fully automated and is easy to use, providing an exceptional user experience in data acquisition, analysis, and reporting.

The product line is an innovative breakthrough in flow cytometry. It capitalizes on the global success of the Agilent line of flow cytometers, including the NovoCyte, the NovoCyte Quanteon, and the NovoCyte Advanteon.

Flow cytometry technology is integral to basic research, drug discovery, and clinical diagnostics. Currently, a major trend in flow cytometry is to measure more parameters simultaneously, especially useful in monitoring for certain blood disorders and in the field of immuno-oncology.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
17/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch